<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078801</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI073</org_study_id>
    <nct_id>NCT05078801</nct_id>
  </id_info>
  <brief_title>Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction</brief_title>
  <official_title>Comparison of Efficacy and Safety of Endoscopic Biliary Drainage and Percutaneous Transhepatic Biliary Drainage for the Management of Perihilar Malignant Biliary Obstruction: a Monocentric Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective monocentric study aims at comparing multimodality endoscopic biliary&#xD;
      drainage versus percutaneous radiologic biliary drainage in case of perihilar malignant&#xD;
      obstruction.&#xD;
&#xD;
      Data from patients admitted in the Nancy University Hospital, France, between january 2016&#xD;
      and march 2022 with jaundice and perihilar obstruction will be retrospectively collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bilirubin serum level</measure>
    <time_frame>7 days</time_frame>
    <description>Diminution of 20% of more on day 7 of the bilirubin serum level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>16 years</time_frame>
    <description>complication-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of procedures</measure>
    <time_frame>16 years</time_frame>
    <description>total number of procedures, including all endoscopic and radiological interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bilirubin serum level on day 30 and on day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival in months</measure>
    <time_frame>16 years</time_frame>
    <description>median survival in month in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of unplanned hospital admissions</measure>
    <time_frame>16 years</time_frame>
    <description>total number of unplanned hospital admissions (for unplanned biliary drainage, cholangitis or other complications...)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Perihilar Cholangiocarcinoma</condition>
  <condition>Jaundice, Obstructive</condition>
  <arm_group>
    <arm_group_label>Endoscopic drainage</arm_group_label>
    <description>All patients with perihilar malignant biliary obstruction treated with endoscopic drainage. This drainage can be multimodal using endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS)-guided biliary drainage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiologic percutaneous drainage</arm_group_label>
    <description>All patients with perihilar malignant biliary obstruction treated with percutaneous drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic drainage</intervention_name>
    <description>ERCP and/or EUS-guided biliary drainage</description>
    <arm_group_label>Endoscopic drainage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous transhepatic biliary drainage</intervention_name>
    <description>US or CT-guided percutaneous drainage</description>
    <arm_group_label>Radiologic percutaneous drainage</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all adults patients hospitalized in Nancy University Hospital with perihilar biliary&#xD;
        malignant obstruction who underwent either endoscopic or percutaneous approach for biliary&#xD;
        drainage.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hospitalization between january 2006 and march 2022&#xD;
&#xD;
          -  perihilar obstruction&#xD;
&#xD;
          -  indication of biliary drainage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distal biliary obstruction&#xD;
&#xD;
          -  perihilar obstruction without indication of biliary drainage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nancy Hospital Center</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>EUS-guided biliary drainage</keyword>
  <keyword>Percutaneous transhepatic biliary drainage</keyword>
  <keyword>hilar obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

